Abstract
OBJECTIVE:
To evaluate both the economic and clinical impact of an intravenous fluconazole restriction policy in a university teaching hospital.
METHODS:
Intravenous fluconazole was restricted to patients unable to take oral medications due to significant nausea or to patients whose oral intake was restricted. A retrospective chart review and computerized record review was conducted in patients receiving intravenous or oral fluconazole from January 1 to June 30, 1997, and again from January 1 to June 30, 1998, after implementation of the policy.
RESULTS:
Six-month institutional expenditures for intravenous fluconazole decreased following policy implementation, from $81 900 to $45 400, an estimated annual institutional savings of $73 000. A 47% reduction in the number of patients treated with intravenous fluconazole was observed over the six-month period after policy implementation. During this time, the rate of successful clinical outcomes for documented or suspected disseminated Candida albicansinfection or febrile neutropenia remained the same (66.6% prepolicy and 65.9% postpolicy; p = 0.95). Similarly, the number of deaths in patients receiving fluconazole remained unchanged (p = 0.31).
CONCLUSIONS:
A restriction policy for intravenous fluconazole results in significant cost savings, with no significant decrease in successful outcomes or change in mortality.
Get full access to this article
View all access options for this article.